Reversal of multidrug resistance in hematological malignancies

Blood Reviews

Volumn 13, Issue 2, 1999, Pages 67-78

  Vossebeld, P J M ^a   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CISPLATIN; COLCHICINE; CYCLOSPORIN A; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXVERAPAMIL; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; PACLITAXEL; QUINIDINE; TAXANE DERIVATIVE; TENIPOSIDE; VALSPODAR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0032992844     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(99)90013-9     Document Type: Article

References (129)

1. Goldic JH, Coldman AJ. Quantitivc model for multiple levels of drug resistance in clinical tumors. Cancer Treatment Reports 1983;67:923 931.
2. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. Journal National Cancer Institute 1989;2:116 124.
3. Borst P. Genetic mechanisms of drug resistance. A review. Acta Oncologica 1991;30:87 105.
4. Lemontt JF, Azzaria M, Gros P. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Research 1988;48:6348 6353
5. Fojo AT, Whang-Peng J, Gottesmann MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proceedings National Academy of Sciences USA 1985;82:7661 7665.
6. Kartncr N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285 1288.
7. Hryeyna CA, Zhang S, Ramachandra M, Ni B, Pastan I, Gottesman M. Functional and molecular characterization of the human multidrug transporter, in Gupta S, Tsuruo T (eds). Multidrug resistance in cancer cells. Chichester, John Wiley, 1996,29-30.
8. Chen CJ, Chin JE, Ueda K et al. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug resistance cells. Cell 1986;47:381 389.
9. Germann UA. P-glycoprotein - A mediator of multidrug resistance in tumour cells. Eur J Cancer 1996;32A:927-944.
10. Germann UA, Chambers TC, Ambudkar SV et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 1996;271:1708-1716.
11. Goodfellow HR, Sardini A, Ruetz S et al. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 1996;271:13668-13674.
12. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993;268:7474-7481.
13. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman M, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493-21496.
14. Raviv Y, Pollard HB, Bruggeman EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265:3975 3980.
15. Bolhuis H, Van Veen HW, Molenaar D, Poolman B, Driessen AJM, Konings WN. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO J 1996;15:4239-4245.
16. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992;17:18-21.
17. Smit JJM, Schinkel AH, Oude Elferink RPJ et al. Homozygous disruption of of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-462.
18. Smith AJ, Timmermans-Hewreijgers JLPM, Roelofsen B et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholinc through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994;354:263-266.
19. Smith AJ, de Vree JM, Ottenhof R, Oude Elferink RP, Schinkel AH, Borst P. Hepatocytespecific expression of the huamn MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in mdr2 (-/-) mice. Hepatology 1998;28:530-536.
20. Van Helvoort A, Smith AJ, Sprong H et al. MDR1 P-glycoprotcin is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-517.
21. Eytan GD, Regev R, Oren G, Assaraf YG. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996;271:12897-12902.
22. Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of PSC 833. a substrate and inhibitor of P-glycorproteins, in various concentrations of serum. J Nat Cancer Inst 1998;90:1161 1166.
23. Arceci RJ. Clinical Significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-2222.
24. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer. British Journal of cancer 1991;63:663-669.
25. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical datection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991;19:131-140.
26. Niehans GA, Jaszcz W, Brunetto V et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse, large cell and immunoblastic lymphomas. Cancer Res 1992;52:3768-3775.
27. Schlaifer D, Laurent G, Chittal S et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 1990;62:177 182.
28. Dalton WS, Grogan T, Rybski J et al. Immunohistochemical detection and quantitation of P-glycoprotein in drug-resistant human multiple myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989;73:747-752.
29. Dan S, Esumi M, Sawada U et al. Expression of a multudrug resistance gene in human malignant lymphomas and related disorders. Leuk Res 1991;15:1139-1143.
30. Rodriguez C, Commes T, Robert J, Rossi JF. Expression of P-glycoprotein and anoinic glutathione S-Transferase genes in non-Hodgkin's Lymphoma. Leuk Res 1993;17:149-156.
31. Chen AL, SU IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and lutathione-S-Transferase in recurrent lymphomas:the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993;11:109-115.
32. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994;12:2453-2459.
33. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesmann MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proceedings National Academy of Sciences USA 1987;84:265-269.
34. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochemical Biophysical Research Communications 1989;165:1415-1421.
35. Sato H, Gottesmann MM, Goldstein LJ et al. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Research 1990;14:11-21.
36. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. British Journal of Haematology 1990; 77:50-53.
37. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 1991;78:586-592.
38. Pirker R, Wallner J, Geissler K et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal National Cancer Institute 1991;83:708-712.
39. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992;6:879-885.
40. Gekeler V, Frese G, Noller R et al. MDR1/Pglycoprotein, topoisomerase, and glutatione-S-transferase π gene expression in primary and relapsed acute adult and childhood leukaemias. British Journal of Cancer 1992;66:507-517.
41. Campos L, Guyotat D, Archimbaud E et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992;79:473-476.
42. Te Boekhorst PAW, De leeuw K, Schoester M, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ leukemia cells. Blood 1993;82:3157-3162.
43. Ino T, Miyazaki H, Tsogai M et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994;8:1492-1497.
44. Lamy T, Goasguen JE, Mordelet E, et al. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994;8:1879-1883.
45. +/Efflux cases. Blood 1995;86:2329-2342.
46. Paietta E, Andersen J, Racevskis J et al. Multidrug resistance gene (MDR1) transcript or CD34 antigen expression levels do not predict for complete remissions in de novo adult acute myeloid leukemia (AML): an Eastern cooperative oncology group study. Blood 1994;84:3771 (abstr).
47. Te Boekhorst PAW, Löwenberg B, Van Kapel J, Nooler K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995;9:1025-1031.
48. List A, Spier CM, Cline A et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. British Journal of Haematology 1991;78:28-34.
49. Guerci A, Merlin HL, Missoun N et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85:2147-2153.
50. Van den Heuvel-Eibrink MM, Van der Holt B, Te Boekhorst PAW et al. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology 1997;99:76 83.
51. Leith CP, Kopecky KJ, Chen IM et al. MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: A southwest oncology group study. Blood 1995;86:286a (abstr).
52. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR 1) and cytogenetics distinguishes biological subgroups with remarkebly distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997;89:3323-3329.
53. Goasguen JE, Dossot JM, Fardel O et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of the novo acute lymphoblastic leukemia: Prognostic implications. Blood 1993;81:2394 2398.
54. Kuwazuru Y, Hanada S, Furukawa T et al. Expression of P-glycoprotein in adult T-cell Leukemia Cells. Blood 1990;76:2065-2701.
55. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of MDR1/P170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. European Journal Haematology 1992;48:254 258.
56. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989;74:913-917.
57. Drenou B, Fardel O, Amiot L, Fauchet R. Detection of P-glycoprotein activity on normal and leukemic CD34+ cells. Leukemia Research 1993;17:1031-1035.
58. Sonneveld P, Schoester M, De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma. Journal of Clinical Oncology 1994;12:1584-1591.
59. Cornelissen J, Sonneveld P, Schoester M et al. MDR-1 expression and response to vincristine, doxorubicin and dexamathasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994;12:115 119.
60. Grogan TM, Spier CM, Salmon SE et al. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993;81:490-495.
61. Miwa H, Kenchiki K, Norihisa M et al. Expression of MDR1 gene in acute leukemia cells: Association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 1993;82:3445 3451.
62. Marie JP, Bastie JN, Coloma F et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993;7:821-824.
63. Ludescher C, Thaler J, Drach D et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. British Journal of Haematology 1992;82:161-168.
64. Sonneveld P, Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myclocytic leukaemia. British Journal of Haematology 1990;75:208-211.
65. Salmon SE, Dalton WS, Grogan TM. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
66. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267-3273.
67. Dalton WS, Grogan TM, Meltzer PS et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology 1989;7:415-424.
68. Burger H, Nooter K, Sonneveld P, Van Wingerden KE, Zaman GJR, Stoter G. High expression of the multidrug resistance-associated protein (mrp) in chronic and prolymphocytic leukaemia. British Journal of Haematology 1994;88:348-356.
69. Hart SM, Gancshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (mrp) in acute leukaemia. Leukemia 1994;48:2163-2168.
70. Schneider E, Cowan KH, Bader H et al. Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia. Blood 1995;85:186-193.
71. Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994;84:3113-3121.
72. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and mrp together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Research 1995;1:81 (abstr).
73. Legrand O, Simonin G, Zittoun R, Maria JP. Comparison of MDR1, MRP and LRP expression with in vitro drug sensitivity in vivo response to treatment in fresh blast cells from adult acute myeloid leukemia patients. Blood 1997;90:180a, (abstr).
74. Van der Kolk DM, de Vries EGE, Koning JA, Van den Berg E, Müller M, Vellenga E. Activity and expression of the multidrug resistance protein MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 1998;4:1727 1736.
75. Baer MR, Swann VL, Shollo MM et al. Frequent coexistence of multiple mechanisms of multidrug resistance in acute myeloid leukemia cells. Blood 1997;90:181a, (abstr).
76. Kuss BJ, Deeley RG, Cole SPC et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994;343:1531-1534.
77. Scheper RJ, Broxterman HJ, Scheffer GL et al. Overexpression of a M 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research 1993;53:1475 1479.
78. List AF, Spier CS, Abbaszadegan M et al. Non-P-glycoprotein (Pgp) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia. Blood 1993;82:443a (suppl 10).
79. Michieli M, Damiani D, Ermacora A et al. P-glycoprotein (Pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology 1997;96:356 365.
80. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G. Modulation of multidrug resistance by verapamil or MDR1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. International Journal of Cancer 1990;46:727 732.
81. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735 2739.
82. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Research 1990;50:1748 1756.
83. Beck WT. Multidrug resistance and its circumvention. European Journal Cancer 1990;26:513 515.
84. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Molecular Pharmacology 1988;33:454-462.
85. Fisher GA, Sikic BJ. Clinical studies with modulators of multidrug resistance (Review) Hematology-Oncology Clinics of North-America 1995;9:363-382.
86. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991;77:348-354.
87. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium channel antagonists and calmoduline inhibitors. Cancer Research 1983;43:2267-2272.
88. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and vinblastine. Cancer Research 1984;44:4303-4307.
89. Twentyman PR. A possible role for Cyclosporins in cancer chemotherapy. Anticancer Research 1988;8:983-993.
90. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of MDRI and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. Journal National Cancer Institute 1990;28:1133-1140.
91. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D Overexpression of the MDR1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. International Journal of Cancer 1990;45:263-268.
92. Ross DD, Wooten PJ, Tong Y et al. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremaphor EL. Blood 1994;83:1337-1347.
93. Ross DD, Wooten PJ, Sridhara R, Ordónez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993;82:1288-1299.
94. Osann K, Sweet P, Slater LM. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistance human leukemia cell lines in vitro. Cancer Chemotherapy Pharmacology 1992;230:152-154.
95. Solary E, Bidan JM, Calvo F et al. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia 1991;5:592-597.
96. Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myclogenous leukemia (AML). Experimental Hematology 1992;20:565-568.
97. Visani G, Fogli M, Tosi P et al. Comparative effects of recemic verapamil vs R-verapamil on normal and leukemic progenitors. Annals of Haematology 1993;66:273-276.
98. Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporin in multidrug-resistant human leukemic cell lines and normal bone marrow. Experimental Hematology 1990;18:1193-1198.
99. Aihara A, Sikic BI, Blume KG, Chao NJ. Assessment of purging with multidrug resistance (MDR) modulators and VP-16: Results of long-term marrow culture. Experimental Hematology 1990;18:940-944.
100. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology 1991;9:17-24.
101. Ozols RF, Cunnion RE, Klecker RW et al. Verapamil and adriamycin in the treatment of drug-resistant ovariancanccr patients. Journal of Clinical Oncology 1987;5:641-647.
102. Jones RD, Kerr DJ, Harnett AN et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. British Journal of Cancer 1990;62:133-135.
103. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastin, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Research 1989;49:1063-1066.
104. Trump DL, Smith DC, Ellis PG et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. Journal National Cancer Institute 1992;84:1811-1816.
105. Philip PA, Joel S, Monkman SC et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: Nifedipine plus etoposide. British Journal of Cancer 1992;65:267-270.
106. Berg S, Tolcher A, O'Shaugncssy JA. Effect of R-Vcrapamil on the pharmacokinetics of paclitaxcl in women with breast cancer. J Clin Oncol 1995;13:2039-2042.
107. Motzer RJ, Lyn P, Fischer P. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-1965.
108. Tolcher AW, Cowan KH, Solomon D et al. Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996;14:1173 1184.
109. Mickish GH, Noordzij MA, Van der Gaast A et al. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1995;121:11 16.
110. Boote D, Dennis I, Twentyman P et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
111. Boesch D, Gaveriaux C, Jachez B, Poutier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Research 1991;51:4226-4233.
112. Drach D, Zhao S, Drach J et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:27292734.
113. Kerr DJ, Graham J, Cummings J et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemotherapy Pharmacology 1986;18:239-242.
114. Linn SC, Van Kalken CK, Van Tellingen O et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. Journal of Clinical Oncology 1994;12:812-819.
115. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. Journal of Clinical Oncology 1994;11:1652-1660.
116. Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-259.
117. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. Journal of Clinical Oncology 1992;10:1635-1642.
118. Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. British Journal of Haematology 1988;68:203 206.
119. Wilson WH, Jamis-Dow C, Bryant G et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995;13:1985-1994.
120. Wilson WH, Bates SE, Fojo A et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
121. Sonneveld P, Marie JP, Huisman C et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vinrristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase 1 study. Leukemia 1996;10:1741 1750.
122. Dalton WS, Crowley JJ, Salmon SS et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology group study. Cancer 1995;75:815-820.
123. Sonneveld P, Suciu S, Weijermans P et al. Cyclosporine A combined with VAD vs VAD in patients with refractory multiple myeloma: An EORTC/HOVON randomized phase II study. Blood 1997;90:356a (abstr).
124. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: Correlation with treatment outcome and MDR1 expression. Leukemia 1993;7:825 831.
125. List AF, Karanes C, Dorr R et al. Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC 833: results of a phase I/II multicenter study. Blood 1996;88:292a (abstr).
126. Kornblau SM, Estey E, Madden T et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997;15:1796-1802.
127. Solary E, Caillot D, Chauffert B et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992;10:1730-1736.
128. Advani R, Saba HI, Tallman M et al. Treatment of poor prognosis AML with PSC 833 plus mitoxantrone, etoposide, cytarabine. Blood 1997;90:356a (abstr).
129. Visani G, Milligan D, Leoni F et al. A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, eloposide and cytarabine in poor prognosis acute leukemia. Blood 1997;90:356b (abstr).